Michael Gemmill

Michael Gemmill serves as a key procurement lead within the National Heart, Lung, and Blood Institute (NHLBI), supporting the agency’s mission to advance biomedical research through the acquisition of high-precision analytical laboratory instrumentation and specialized research infrastructure. He manages complex contracting actions for cutting-edge scientific equipment, including mass spectrometers, next-generation sequencers, and single-cell analysis platforms, ensuring alignment with NHLBI’s strategic priorities in precision medicine and biologic data systems. His acquisitions directly enable foundational research in cardiovascular, pulmonary, and hematologic disorders, requiring deep technical understanding of laboratory automation, bioinformatics integration, and regulatory compliance for research-grade devices. Gemmill maintains longstanding relationships with a select group of institutional and industry partners, including the University of Mississippi Medical Center, Wake Forest University Health Sciences, and TDA Research, Inc., reflecting a preference for research-intensive academic medical centers and innovative small technology firms. These partnerships are characterized by collaborative procurement planning, performance-based contract structures, and a focus on technical capability over cost alone. His contracting approach emphasizes long-term scientific continuity, often supporting multi-year instrument deployment and service agreements critical to sustained research output. Gemmill’s portfolio exhibits no set-aside preferences, with 100% of awards issued under full and open competition. This reflects a mission-driven prioritization of technical excellence and scientific readiness over socioeconomic targeting, though small businesses remain active participants due to their specialized capabilities in niche analytical instrumentation. His contracting patterns demonstrate a deliberate focus on capability-driven selection rather than socioeconomic categorization. His primary procurement activity centers on NAICS 334516—Analytical Laboratory Instrument Manufacturing—where he specializes in procuring advanced diagnostic and genomic analysis systems. His domain expertise spans proteomics, metabolomics, and high-throughput biological data acquisition platforms, ensuring NHLBI’s research ecosystem remains at the forefront of biomedical innovation.